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Sonic hedgehog (Shh) binds to its receptor patched (PTCH), leading to the activation and repression of target
genes via the GLI family of zinc-ﬁnger transcription factors. Deregulation of the Shh pathway is associated with
basal cell carcinoma (BCC) due to upregulation of GLI1 and GLI2. We recently demonstrated a positive feedback
loop between GLI1 and GLI2, which revealed that GLI1 may be a direct target of GLI2. Using band shift and
luciferase reporter assays, we now show that GLI2 binds the GLI-binding consensus sequence in the GLI1
promoter. These data suggest that GLI2 directly activates GLI1 and that retrovirally expressed GLI2 induces
expression of endogenous GLI1 in human primary keratinocytes. Finally, using in situ hybridization, we show that
GLI2 is expressed in the interfollicular epidermis and the outer root sheath of hair follicles in normal skin as well as
in BCC tumor islands. These results suggest an important role for GLI2 in regulating epidermal proliferation and
skin tumorigenesis.
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Hedgehog (Hh) signal transduction pathway plays an
essential role in a number of Drosophila and vertebrate
developmental processes, including cell type specification,
pattern formation, and regulation of cell proliferation. Much
of our understanding of this pathway comes from studies
carried out in Drosophila, in which Hh modulates gene
expression through the zinc-finger-containing transcription
factor Cubitus interruptus (Ci). Ci can function as either a
transcriptional activator or a proteolytically cleaved repres-
sor (Aza-Blanc and Kornberg, 1999). In vertebrates, trans-
criptional responses to Hh signalling are mediated by the
three Ci homologues, Gli1, Gli2, and Gli3 (Matise and Joyner,
1999; Ruiz i Altaba, 1999; Ingham and McMahon, 2001), that
can act in a combinatorial fashion to modulate target gene
expression. Gli1 and Gli2 appear to act primarily as
transcriptional activators, whereas Gli3 (and at times GLI2)
functions as a repressor (Ingham and McMahon, 2001).
Genetic analysis of patients with familial nevoid basal cell
carcinoma syndrome (NBCCS) as well as individuals with
sporadic BCC led to the identification of the PTCH tumor
suppressor gene (Gorlin, 1987; Hahn et al, 1996; Johnson et
al, 1996); this subsequently implicated aberrant sonic
hedgehog (Shh) signalling in BCC formation. Indeed,
upregulation of GLI1 and GLI2 is frequently observed in
BCCs (Gailani et al, 1996; Dahmane et al, 1997; Unden et al,
1997; Regl et al, 2002). Further evidence for BCC develop-
ment as a result of activation of Hh-signalling pathway
comes from transgenic mouse models and skin grafting
techniques. Heterozygous Ptchþ /mice develop BCC-like
features upon UV irradiation, although sporadic BCC
formation does not normally occur in these mice (Aszter-
baum et al, 1999). Human keratinocytes expressing Shh
form BCC-like structures when grafted onto the back of
nude mice (Fan et al, 1997) and overexpression of
mediators of Hh-signalling including an oncogenic form of
SMO, Shh, GLI1, and GLI2 in epidermal cells of transgenic
mice leads to the induction of BCC-like tumors (Fan et al,
1997; Oro et al, 1997; Xie et al, 1998; Grachtchouk et al,
2000; Nilsson et al, 2000).
The predominance of either GLI1 or GLI2 activation with
regard to BCC formation is unclear; however, we recently
identified a positive feedback loop between these two
proteins, which suggested that GLI1 is an early target of
GLI2, whereas GLI2 is likely to be an indirect target of GLI1
(Regl et al, 2002). We now present data showing that GLI2
specifically binds to the GLI1 promoter, suggesting that
GLI1 is a direct target of GLI2. Furthermore, we show that
retrovirally expressed GLI2 induces endogenous GLI1
expression in human primary keratinocytes. Finally, using
in situ hybridization, we show that GLI2 is expressed in the
outer root sheath (ORS) of the hair follicle as well as in BCC
tumor islands. These findings suggest that GLI2 directly
activates GLI1 expression and may play an important role in
skin tumorigenesis.
Results
NHIS-GLI2 binds GLI consensus sequence in the GLI1
promoter and induces GLI1 expression in human
primary keratinocytes We have previously identified a
Abbreviations: Shh, sonic hedgehog; BCC, basal cell carcinoma;
Hh, hedgehog; ORS, outer root sheath
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positive feedback loop between GLI2 and GLI1 in primary
human keratinocytes. In particular, time-course analysis of
GLI1 mRNA expression in GLI2 expressing keratinocytes
provided preliminary evidence for GLI1 possibly being a
direct target of GLI2 (Regl et al, 2002). To investigate this in
more detail, we have measured the increase in GLI1 mRNA
and protein in a sub-line of the human keratinocyte cell line
HaCaT (GLI2-HaCaT), which expresses N-terminally HIS-
tagged GLI2 protein (NHIS-GLI2) under control of the
tetracycline repressor. Furthermore, we have related the
increase in GLI1 mRNA and protein to levels of NHIS-GLI2
protein. Figure 1a shows that following tetracycline treat-
ment, there was a gradual increase in GLI1 mRNA. In
addition, activation of the direct target gene PTCH was
slightly delayed compared with induction of GLI1 mRNA.
Western blot analysis (Fig 1b) showed that NHIS-GLI2
protein was detected 1 h after tetracycline treatment,
whereas GLI1 protein was not detected until 6 h after
treatment. Moreover, the increase in GLI2 protein is closely
paralleled by the gradual increase in GLI1 mRNA. This
suggests that GLI1 represents an early GLI2 target gene.
Figure 1a also shows that GLI1 mRNA induction is
closely followed by a gradual increase in endogenous GLI2
mRNA. This confirms our previous observation that a
positive feedback loop exists between GLI1 and GLI2 (Regl
et al, 2002). In addition to studies in immortalized HaCat
cells, we have also shown in this study (Fig 2a, b) that
endogenous GLI1 expression is induced in retrovirally
transduced GLI2 primary keratinocytes, thus confirming
that GLI1 is a target of GLI2 in primary as well as
immortalized cell lines. This suggests that there is also a
positive feedback between GLI1 and GLI2 in human primary
keratinocytes and this may be important for tumor forma-
tion.
To assess whether GLI2 may be capable of directly
activating GLI1 transcription by binding to the GLI1
promoter, we first performed in silico analysis of the 50
flanking region of the human GLI1 core promoter region (Liu
et al, 1998; Villavicencio et al, 2002) to identify putative GLI-
binding sites. Using the ScanAce tool (Roth et al, 1998;
Hughes et al, 2000), we analyzed a region of approximately
1 kb upstream of the transcriptional start site of GLI1 (Liu
et al, 1998) for motifs identical to or closely matching
the GLI-consensus-binding site TGGGTGGTC (Kinzler and
Vogelstein, 1990) (Fig 3a). An identical putative-binding site
is also present in the cis-regulatory sequence of the mouse
Gli1 gene, suggesting a possible functional relevance of this
motif in the regulation of Gli1 expression (Fig 3b).
To determine whether NHIS-GLI2 protein can bind to the
putative GLI-binding site in the GLI1 core promoter, we
performed electrophoretic mobility shift assays using
bacterially expressed NHIS-GLI2-(332) protein and radio-
actively labelled double-stranded oligonucleotides contain-
ing either the putative GLI-binding site (Bs) or a mutated
control oligonucleotide with two base pair exchanges in the
core region (Bsm). As shown in Fig 4, recombinant NHIS-
GLI2-(332) protein specifically binds to the Bs sequence,
but not to the Bsm sequence, suggesting that NHIS-GLI2
protein may be activating GLI1 transcription by directly
Figure 1
Time-course studies of GLI1, PTCH, and endogenous GLI2 mRNA
and NHIS-GLI2 and GLI1 protein expression in NHIS-GLI2 HaCaT
cell line. Quantitative real-time RT-PCR (a) and western blot analysis
(b). NHIS-GLI2-HaCaT cells were treated with tetracycline for the times
indicated. Real-time RT-PCR data show the mean fold induction
calculated from three independent experiments, each carried out in
duplicate. Standard deviation was below 20% between all replicate
experiments. Large ribosomal protein P0 (RPLPO) was used as a
reference standard for all analyses to control for the amount of sample
material (Martin et al, 2001). Samples for western blot analysis were
normalized for total protein and quantitated by densitomety.
Figure2
GLI1 mRNA and protein expression in NHIS-GLI2 human primary
keratinocytes. Human primary keratinocytes were transduced with
NHIS-GLI2, GLI1, and GFP retrovirus and cultured for 72 h after which
total RNA and proteins were extracted. This figure shows exogenous
NHIS-GLI2 induced endogenous GLI1 protein expression as shown by
(a) semi-quantitative RT-PCR and (b) western blot analysis; Pan-ERK
indicates equal protein loading. Retroviral expression of GLI1 was used
as a positive control, GFP and dH2O as negative controls. The data
represented are of two independent experiments.
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binding to the 50 flanking region of the GLI1 promoter at a
position close to the transcriptional start site.
To analyze whether the GLI-binding site in the GLI1
promoter is involved in activation of GLI1 transcription by
GLI2, we performed luciferase reporter assays using wild-
type and mutated GLI1 promoter constructs. Co-transfec-
tion of GLI2 expression plasmid with the reporter construct
containing the 50 upstream region of human GLI1 (1400
to þ 93, Liu et al, 1998) resulted in a 3-fold increase
in luciferase activity compared with controls. By contrast,
no increase in reporter activity was observed when the
Gli-binding site at position 56 was changed from CGGG
TGGTC to CGCCTGGTC by site-directed mutagenesis
(Fig 5). The GLI-binding and luciferase reporter assay data
suggest that HIS-GLI2 activates transcription of GLI1 by
interacting directly with the GLI-binding site at positions
56 to 48 of the GLI1 promoter.
GLI2 is expressed in BCC, normal interfollicular epider-
mis, and in the ORS of the hair follicle The expression
profile of GLI1 is well characterized in BCC and normal skin
(Ghali et al, 1999). Having shown that GLI1 is a putative
direct target of GLI2, we investigated the expression pattern
of GLI2 in BCC and normal skin by in situ hybridization
(Fig 6). We report that GLI2 mRNA was expressed in BCC
tumor islands of all BCC samples analyzed (n¼8) and in
normal skin (n¼ 3), GLI2 was expressed in the ORS of the
hair follicle, sebaceous glands, and in the interfollicular
epidermis. No staining was observed with a GLI2 sense
probe in adjacent serial sections. Only samples showing a
positive signal for keratin 14 (to confirm RNA integrity) were
analyzed.
Discussion
Members of the GLI family of zinc-finger transcription
factors are key mediators of Hh-signalling and in BCC
activation of the Hh pathway results in overexpression of
GLI1 and GLI2 (Green et al, 1998; Regl et al, 2002). In
primary human keratinocytes, retrovirally expressed GLI1
induces GLI2 expression and in HaCaT cells it has been
shown that a positive feedback loop between GLI1 and
GLI2 exists (Regl et al, 2002). In this study, we have shown
by RT-PCR and western blot analysis that retrovirally
expressed GLI2 induces endogenous GLI1 expression in
primary keratinocytes, confirming that a positive feedback
loop between GLI1 and GLI2 exists. Time-course analysis of
GLI1 expression in GLI2-inducible cell line suggested that
GLI1 may be a direct target GLI2 (Regl et al, 2002). Using
gel shift and luciferase assays, we have identified a
functional Gli-binding site in the GLI1 promoter that confers
activation of GLI1 transcription in response to GLI2. Toge-
ther with detailed time-course studies of GLI1 transcription
Figure 3
Organization of the human and mouse GLI1 core
promoter region. (a) The putative GLI-binding site
at position 56 is highlighted in bold underlined
capital letters, and the first non-coding exon is
shown in upper case italics. Transcriptional start
sites are indicated by bold underlined letters (Liu et al,
1998; Kinzler and Vogelstein, 1990). (b) Sequence
alignment of human (hGLI1 prom) and mouse Gli1
(mGli1 prom) 50 flanking regions. The putative GLI-
binding site in the human core promoter is 100%
identical to the corresponding sequence in the
mouse promoter region. The putative-binding sites
are shown in bold underlined letters. The first exon
sequence of GLI1 is shown in bold italics. Asterisks
represent conserved nucleotides.
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in GLI2 expressing cells, these data suggest direct activa-
tion of GLI1 by GLI2; however, it is possible that the
behavior of the NHIS-GLI2 and the endogenous GLI2
protein may not be identical. Finally, we have shown by
in situ hybridization that GLI2 mRNA is expressed in both
the interfollicular epidermis and ORS of hair follicles as well
as in BCC tumor islands.
The importance of Shh-Gli2 signalling in murine hair
follicle development has been demonstrated by several
groups (St-Jacques et al, 1998; Chiang et al, 1999; Karlsson
et al, 1999; Brewster et al, 2000; Bai et al, 2002; Mill et al,
2003) and transgenic mice expressing GLI2 in the basal
layer develop BCC (Grachtchouk et al, 2000). As expected
for a target of GLI2, the expression profile of GLI1 correlates
with that of GLI2 in both the ORS of the hair follicle and in
BCC. Antibodies to GLI2 are not available and, therefore,
we have been unable to confirm that the patterns of GLI2
protein mimic those of its mRNA. We have shown that in
primary human keratinocytes GLI2 induces GLI1, therefore,
the lack of GLI1 expression may indicate that GLI2 is not
activated in the interfollicular epidermis and that other
factors may be required for transcriptional activity. It has
recently been demonstrated in transgenic mice that Gli2
activation in mouse skin is dependent on Shh. However, it
has been shown that during embryogenesis, Gli2 can be
activated in response to FGF independent of Shh, providing
evidence that GLI2 can function independent of Shh.
Moreover, it has also been shown that deletion of the
N-terminal repressor domain of GLI2 produces a mutant
protein that can induce Gli1 and Ptch expression indepen-
dent of Shh (Sasaki et al, 1999; Brewster et al, 2000; Mill
et al, 2003). Currently, little is known about processing
of GLI2 and it will be important to determine, therefore,
whether GLI2 is processed and if so whether differences in
processing occur between normal skin compartments, such
as interfollicular epidermis, ORS of hair follicle and in BCC.
We have recently found that GLI2 represses expression of
genes associated with epidermal differentiation, suggesting
that GLI2 may have repressor activity in the human
epidermis (Regl et al, in press).
In BCC, GLI1 and GLI2 are consistently expressed in
tumor islands and this may be accounted for by the positive
feedback mechanism that we have identified (Green et al,
1998; Regl et al, 2002). Autoregulation of Gli1 expression
has previously been observed in frog embryos, suggesting
that positive feedback loops may be a common feature to
sustain pathway activation in the absence of Shh stimula-
tion (Dahmane et al, 2001). Whether Gli1 or Gli2 is the initial
factor that induces the feedback loop and possibly tumor
formation remains to be determined. In contrast to Gli1,
expression of Gli2 is not dependent on Shh and during
mouse embryogenesis Gli2 is expressed before the onset of
Shh and Gli1 transcription (Bai et al, 2002). In addition, Gli2
is required for the expression of Gli1 in murine skin (Mill
et al, 2003). This suggests that Gli2 induces Gli1, which in
turn further increases Gli2 levels leading to hyperprolifera-
tion (Regl et al, 2002).
In summary, we provide further evidence for a positive
feedback loop between GLI1 and GLI2 that potentiates the
Shh signal in hair follicle morphogenesis and BCC forma-
tion. This indicates a possible important role for human GLI2
in regulating skin tumorigenesis.
Materials and Methods
Cell culture The study was approved by the local ethical
committee (ELCHA Research Ethics Committee, Ref: T/01/037
and adhered to the declaration of Helsinki guidelines for use of
Figure 4
NHIS-GLI2-(332) binds GLI consensus sequence. Electrophoretic
mobility shift assay demonstrating specific binding of NHIS-tagged
recombinant GLI2 protein corresponding to amino acids 1–332 (NHIS-
GLI2-(332)) to the GLI-binding site (Bs) in the GLI1 core promoter region
(indicated by the band shift). The Bs oligonucleotide sequence used for
the analysis is shown below. The region with a high sequence similarity
to the GLI-consensus-binding site is underlined. The two central
nucleotides shown in capital letters (TG) were changed to AA to give
rise to mutated Bsm. The synthetic polymer poly-(dI–dC) was used in
DNA-binding protein studies to absorb non-specific-binding proteins.
Excess competitors unlabelled Bsm, Bs, and poly-(dI–dC) were used
with 32P-labelled (Bsm 32P) and (Bs 32P).
Figure 5
Luciferase reporter assays showing activation of the GLI1
promoter by NHIS-GLI2. 293 cells were either transfected with wild-
type (GLI1prom-WT) or mutated GLI1 promoter reporter construct
(GLI1prom-Mut), together with either empty vector or NHIS-GLI2
expression vector. Data represented are of mean values of three
independent experiments as relative luciferase units (RLU). These data
show a 3-fold increase in luciferase activity in GLI2/GLI1prom-WT
compared with controls. By contrast, no increase in reporter activity
was observed when the Gli-binding site at position 56 was mutated
from CGGGTGGTC to CGCCTGGTC (GLI2/GLI1 prom-Mut).
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human tissue.) HaCaT cells were grown at 371C in Dulbecco’s
modified medium (DMEM) adjusted to pH 7.5 with 5 mM HEPES,
containing 10% fetal calf serum (FCS), 100 mg per L streptomycin,
and 62.5 mg per L penicillin. Double-stable HaCaT lines,
expressing N-terminally HIS-tagged human GLI2 (GenBank GI
No. 3061315) (NHIS-GLI2) under the control of the tetracycline
repressor, were generated using the T-REX system (Invitrogen,
Carlsbad, CA). NHIS-GLI2 expression was induced by culturing
cells in DMEM-high glucose (Invitrogen), containing 10% FCS and
1 mg per L tetracycline (Invitrogen). Primary human keratinocytes
were isolated and cultured according to the methods described in
Regl et al (2002).
Vector construction and retroviral transduction of primary
keratinocytes and cell transfections The retroviral SIN-GLI1-
EGFP construct was generated as described in Regl et al (2002).
To generate the retroviral bicistronic GLI2-EGFP expression
construct, N-terminally HIS-tagged GLI2 was cloned into pI2E-A,
a modified version of the pIRES2-EGFP plasmid (Clontech,
Hampshire, UK) (Regl et al, 2002), PI2E-A-GLI2 was digested with
SalI and NotI to excise CMV-GLI2-IRES-EGFP. The resulting
fragment was cloned into XhoI–NotI digested retroviral SIN-IP
plasmid (a gift from Prof. P. Khavari) to create SIN-GLI2-EGFP.
Retroviral transduction of primary keratinocytes and cell transfec-
tions were carried out as described in Regl et al (2002). Cells were
harvested at the time points indicated in the text.
RNA isolation and real-time RT-PCR analysis Isolation of total
RNA from HaCaT cells and real-time RT-PCR was carried out as
described previously in Regl et al (2002). Total RNA from primary
keratinocytes was isolated using RNAzol B (Biogenesis Ltd, Poole,
Dorset, UK) as per the manufacturer’s instructions. Genomic DNA
was removed by treatment with DNaseI (Boeringer Mannheim,
Roche; Basal, Switzerland) and cDNA was synthesized using AMV
Reverse Transcriptase (Promega A5000 kit, Madison, WI) accord-
ing to the manufacturer’s instructions. PCR was carried out using
1 mL cDNA reaction, 0.25 mM each dNTP, 1  (25 mM (NH4)2SO4,
93.75 mM Tris-HCl, pH 8.8, at 251C, 1.25  102 Tween 20)
reaction buffer, 1.75 mM MgCl2, 0.125 mM each (forward and
reverse) primers with 1 U thermal stable Red Hot DNA polymerase
(Advanced Biotechnology, Epsom, UK) in a total reaction volume of
20 mL. The samples were thermo cycled, at 941C for 1 min (941C for
1 min, 601C for 30 s, 721C for 1 min)  40 cycles, and final exten-
sion at 721C for 10 min. G6PDH was amplified with an annealing
temperature set at 551C in 35 cycles. A negative primer-only con-
trol without cDNA was also set up. PCR-primer sequences were
as follows: GLI1 forward primer 50 gaagacctctccagcttgga 30
corresponding to 1504–1523 nucleotides and reverse primer 50
ggctgacagtataggcagag 30 corresponding to 1728–1747 nucleo-
tides of GLI1 (GenBank GI No. 4885278). G6PDH forward primer 50
gttccgtgaggaccagatctac 30 corresponding to 584–605 nucleotides,
reverse primer 50 ggctccttgaaggtgaggataa 30 corresponding to
712–733 nucleotides of G6PDH (GenBank GI No. 182870).
Western blot analysis Western blot analysis of GLI1 and NHIS-
GLI2 protein expression was carried out as described in Regl et al
(2002). GLI1 protein was detected with polyclonal goat anti-GLI1
antibody (C-18, Santa Cruz Biotechnology, Santa Cruz, CA) and
NHIS-GLI2 with peroxidase-conjugated monoclonal anti-polyhisti-
dine antibody (Sigma, clone HIS-1, Sigma, Vienna Austria; Dorset,
UK). Proteins were visualized by chemiluminescence detection
(ECL, Amersham Biosciences, Bucks, UK; Uppsala, Sweden).
Proteins levels were quantified by densitometric analysis using the
AIDA/2D densitometry software package (RAYTEST).
Recombinant GLI2 protein expression and puriﬁcation For the
production of recombinant GLI2 protein, a fragment encoding
amino acids 1–386 of GLI2 was PCR amplified using the following
primers: forward: 50 gagggatccgccctcacctccatcaat 30, reverse: 50
gaggaattcctaggtcatcatgttcagg 30. The amplicon was cloned into
Figure 6
In situ hybridization analysis of GLI2 expression
in basal cell carcinoma (BCC) and normal skin.
GLI2 expression was detected in the epidermis (a,
o, q) and in the outer root sheath of the hair follicle
(c, e, g) with an anti-sense probe. No staining was
observed in adjacent sections with a sense probe
(b, d, f, h, p, r). GLI2 expression was detected in
BCC tumor islands with an anti-sense probe (i, k,
m). No staining was observed in adjacent sections
with a sense probe ( j, l, n).
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the EcoRI–BamHI sites of Escherichia coli expression vector pHIS-
Parallel2 (Sheffield et al, 1999). To increase the solubility of GLI2
protein, the insert was further truncated at the C-terminus with
SmaI and XhoI yielding a protein corresponding to amino acids
1–332, which encompasses the N-terminus and the entire zinc-
finger DNA-binding domain (NHIS-GLI2-(332)). NHIS-GLI2-(332)
protein expression in E. coli strain BL21 was induced for 60 min by
the addition of 1 mM IPTG (Sigma). HIS-tagged GLI2-(332) protein
was purified with Ni-NTA Agarose (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions.
Electrophoretic mobility shift assay Binding reactions for band
shift assays were carried out in 1  BS buffer (20 mM Tris, pH7.8,
25 mM KCl, 5 mM MgCl2, 0.5 mM DTT, and 10 mM ZnSO4)
containing 0.77 mg poly-(dI–dC) (Sigma) and 10% glycerol. Five
micrograms of purified NHIS-GLI2-(332) protein and 8 ng of
radioactively labelled double-stranded oligonucleotide were added
to the reaction and incubated for 25 min at room temperature. In
competition experiments, 400 ng of specific or mutant unlabelled
oligonucleotide were used per reaction. For unspecific competi-
tion, 1.5 mg poly-dI–dC was added to the reaction. Samples were
separated on 6% acrylamide gels. Following electrophoresis, gels
were dried, exposed overnight, and scanned with a BAS-1800II
phosphoimager (Fuji, Fuji, Japan).
Luciferase reporter assays and site-directed mutagenesis The
50 upstream regulatory region of the human GLI1 gene from 1400
to þ 93 relative to the transcriptional start site (Liu et al, 1998) was
amplified by PCR using the FailSafe PCR system for high-fidelity
PCR cloning (Epicentre, Madison, WI). To mutate the Gli-binding
site, the GLI1 promoter was first subcloned into pBluescript II
SKþ (Stratagene, La Jolla, CA) and then subjected to site-directed
mutagenesis with the QuickChange Kit (Stratagene, La Jolla, CA)
according to the manufacturer’s instructions. Following mutagen-
esis, the GLI1 promoter region was transferred back to pGL3
reporter vector. The sequence of the oligonucleotide used for
mutagenesis was 50 GCGCTTCTCGCGCCTGGTCCGGGCTTG 30.
Successful mutagenesis was verified by DNA-sequencing on an
ABI 310 automated sequencer. For luciferase reporter assays, 293
cells were co-transfected in 12-well plates with GLI2 expression
plasmid (GLI2b in pcDNA4/TO, Invitrogen) or empty pcDNA4/TO,
and wild-type or mutated GLI1 reporter plasmid. b-galactosidase
expression vector (pcDNA4/TO-LacZ, Invitrogen) was co-trans-
fected for normalization of transfection efficiency. Cells were
harvested at 48 h post-transfection and luciferase assays were
carried out using Luciferase Assay Substrate (Promega), according
to the manufacturer’s instructions. Luciferase activity was mea-
sured on a Lucy II luminometer (Anthos, Wals, Austria). To
normalize results for lacZ activity, 10 mL of cell lysate was mixed
with 240 mL Z-buffer (100 mM NaPO4 (pH 7), 10 mM KCl2, 1 mM
MgSO4, 50 mM b-Mercaptoethanol), and 50 mL O-nitro-a-D-
phenyl-galactopyranoside (4 mg per mL) and incubated at 281C
until yellow staining became visible. Reactions were stopped by
adding 250 mL 1 M NaCO3. b-galactosidase activity was quantified
by measuring absorbance at 405 nm on an SLT-Spectra plate
reader (SLT, Austria).
In situ hybridization GLI2 and keratin 14 sense and anti-sense
probes were generated from GLI2 cDNA corresponding to 28,270–
28,566 nucleotides (GenBank GI No. 3061315) and keratin 14
cDNA corresponding to 298–1498 nucleotides (GenBank GI No.
15431309) cloned into pCRII-TOPO vector, using DIG-labelling kit
(Roche, Basal, Switzerland; Lewes East Sussex, UK) as described
by the manufacturer’s instructions. Keratin 14 probes were
fragmented and purified using sodium acetate ethanol precipita-
tion method (Wilkinson, 1998). Eight micrometer tissue sections
were pre-hybridized with (4  SSC, 1  Denhardt’s, 50% forma-
mide (500 mg per mL tRNA and 500 mg per mL Salmon Testes DNA
denatured at 1001C for 10 min and placed on ice) before adding to
the mix) and incubated at 421C for 3–4 h. Hybridization was carried
out using fresh pre-hybridized solution containing (80–100 ng
labelled probe denatured at 651C for 5 min) at 421C overnight. The
next day, the sections were washed in 2  SSC for 5 min (  2) and
in (2  SSC, 1  SSC, 0.5  SSC each containing 50% forma-
mide) at 45–551C and in 0.1  SSC 50% formamide at 50–601C for
20 min, followed by a final wash in 2  SSC and rinsed in DIG
buffer 1 (100 mM Tris-HCl, 150 mM NaCl, pH 7.5). Sections were
blocked with 10% normal sheep serum (NSS) in DIG buffer 1 and
incubated with anti-digoxigenin-alkaline phosphatase conjugated
(Roche) diluted 1:400 in 1% NSS DIG buffer 1 for 2 h, followed by
washing in DIG buffer 1 (  2) and DIG buffer 2 (100 mM Tris-HCl,
pH 9.5, 100 mM NaCl, 50 mM MgCl2) for 10 min. The Hybrids were
visualized by incubating the section with BCIP/NBT (Sigma) liquid
substrate in the dark at 41C overnight. The color reaction was
stopped by immersing the sections in (10 mM Tris-HCl, pH 8, 1 mM
EDTA) for 30 min. The developed slides were mounted and
examined by microscopy.
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